Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl
about
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl
description
scientific article published on 15 April 2019
@en
name
Inotuzumab ozogamicin in combi ...... mosome-negative acute lymphobl
@en
type
label
Inotuzumab ozogamicin in combi ...... mosome-negative acute lymphobl
@en
prefLabel
Inotuzumab ozogamicin in combi ...... mosome-negative acute lymphobl
@en
P2093
P50
P356
P1433
P1476
Inotuzumab ozogamicin in combi ...... a: A propensity score analysis
@en
P2093
Farhad Ravandi
Ghayas C Issa
Jovitta Jacob
Marina Konopleva
Monica Kwari
Musa Yilmaz
Naveen Pemmaraju
Nitin Jain
Philip Thompson
Rebecca Garris
P304
P356
10.1002/CNCR.32139
P50
P577
2019-04-15T00:00:00Z